Connect with us

MEDICAL

New herpes zoster vaccine predicted to be more cost effective than predecessor  

Liberty Peters

Published

on

1. In a computational model, the new “recombinant zoster vaccine” (RZV) was predicted to be most cost-effective than the previous gold standard, the zoster vaccine live (ZVL).

2. The RZV vaccine was predicted to perform better even if only half of patients received the second dose.

Evidence Rating Level: 4 (Below Average)

Study Rundown: A new Herpes zoster (HZ) vaccine called the “recombinant zoster vaccine” (RZV) was approved by the FDA in 2017.  In clinical trials, the RSV was shown to have a higher efficacy than the former gold standard, the “zoster vaccine live” (ZVL).  In this study, a computational model was used to compare the RZV to the ZVLvaccine  using data from a number of published studies.  For all age groups from 50-99, RZV cost less and prevented more cases of HZ, resulting in a favorable incremental cost-effectiveness ratio (ICER).  Notably, their data showed that vaccination with RZV was cheaper than non-vaccination for patients aged 50-59, an age group that did not routinely receive the ZVL vaccine.  As with any simulation, these results were reliant upon a number of assumptions about disease prevalence, symptom severity, and patient and physician compliance with recommendations.  The authors demonstrated that their conclusions were robust to variation in most of these parameters, but duration of vaccine efficacy remained a significant concern.  The ZVL vaccine has been shown to wane significantly over 11 years, and there are not yet sufficient data to determine if the RZV will have similar limitations.

Click to read the study in Annals of Internal Medicine

Click to read the accompanying editorial in Annals of Internal Medicine

Relevant Reading: Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

In-Depth [simulation]:  This study constructed a computational model to predict the societal cost-effectiveness of different vaccination regimes.  Using published data for the RZV and ZVL vaccines, the authors determined that the RZV vaccine was cheaper and had more health benefits for each age group between 50 and 99.  The primary outcome was the incremental cost-effectiveness ratio (ICER), which is measured in dollars per quality-adjusted life year (QALY).  On a decade by decade basis, the predicted ICER score ranged from $1,000/QALY to $4,700/QALY.  Though the incremental cost was highest for patients aged 50-59, the vaccine was still considered to be economically favorable.  Since it can be difficult to predict adherence for a multiple-injection vaccine series, the authors also confirmed that ICER remains cost effective even if only 50% of patients receive the second dose.  The results were similarly robust to a number of other variables, including incidence of HZ, incidence of post-herpetic neuralgia, and severity of post-vaccination symptoms.  However, their conclusions relied upon sustained vaccine efficacy, which has been a major limitation of the ZVL vaccine.

©2019 HPSN. All rights reserved. No works may be reproduced without expressed written consent from HPSN. Join our world acclaimed Facebook group here. No article should be construed as medical advice and is not intended as such by the authors or by HPSN.

Member and content contributor for the Human Parasites Support Network. Also co-hosts on the HPSN talk show. Survivor and victim of parasitic infections.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Medical News

#CDC

Along with monitoring babies’ development, it is important for parents to make sure their baby is up to date on all recommended childhood #vaccines. Talk to your pediatrician at her next appointment.

Adverse childhood experiences (ACEs) impact lifelong health & opportunities. 1 in 6 adults experienced four or more types of ACEs. Learn more about prevention strategies & the link between #ACEs and 14 negative outcomes in the #VitalSigns report: bit.ly/VitalSignsACEs

NEW: Antibiotic-resistant bacteria & fungi cause more than 2.8M infections and 35k deaths in the United States each year, according to the second #CDCARthreats Report released today. Progress has been made, but aggressive action must continue. bit.ly/CDCARthreats

test Twitter Media - NEW: Antibiotic-resistant bacteria & fungi cause more than 2.8M infections and 35k deaths in the United States each year, according to the second #CDCARthreats Report released today. Progress has been made, but aggressive action must continue. https://t.co/9Xe13lzETS https://t.co/2miM9mA0A3

#LymeDisease

@MediSieve @uclnews @UCLAlumni @UCLBiochemEng1 Thanks, sounds positive. Please keep me posted with any clinical trials in this area as I'd be interested in participating #LymeDisease #Hope

@StylesSa191919 @uclnews @UCLAlumni @UCLBiochemEng1 We haven't looked into #LymeDisease in detail, but it's an interesting idea. Theoretically we could look to remove Borrelia bacteria from the bloodstream, but we wouldn't be able to get any that had "settled" in areas of the body, so we'd need to think about the clinical pathway

According to the CDC, 94% of all vector-borne diseases in the US come from tick bites. #OneHealth #LymeDisease twitter.com/CDC_NCEZID/sta…

Researcher "observed a never-before-seen phenomena demonstrating... the [Lyme] bacteria can spring back in the body weeks later." #LymeDisease #ImmuneSupression lymedisease.org/lyme-outsmarts…

#NTD’s

No result could be fetched.

Trending

Copyright © 2019. All Rights Reserved. The Human Parasite Support Network.